Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

× No keyword cloud information.

21 in total

1. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.

Authors: Daniel N Cohen; Steven K Lawson; Aaron C Shaver; Liping Du; Harrison P Nguyen; Qin He; Douglas B Johnson; Wilfred A Lumbang; Brent R Moody; James L Prescott; Pranil K Chandra; Alan S Boyd; Jeffrey P Zwerner; Jason B Robbins; Stephen K Tyring; Peter L Rady; James D Chappell; Yu Shyr; Jeffrey R Infante; Jeffrey A Sosman
Journal: Clin Cancer Res Date: 2015-02-27 Impact factor: 12.531

Review 2. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Authors: Matthew Holderfield; Marian M Deuker; Frank McCormick; Martin McMahon
Journal: Nat Rev Cancer Date: 2014-07 Impact factor: 60.716

3. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Authors: Ross A Okimoto; Luping Lin; Victor Olivas; Elton Chan; Evan Markegard; Andrey Rymar; Dana Neel; Xiao Chen; Golzar Hemmati; Gideon Bollag; Trever G Bivona
Journal: Proc Natl Acad Sci U S A Date: 2016-11-09 Impact factor: 11.205

Review 4. BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors: M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal: Horm Cancer Date: 2014-12-03 Impact factor: 3.869

Review 5. Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

Authors: Adrianus J de Langen; Egbert F Smit
Journal: Ther Adv Med Oncol Date: 2016-10-03 Impact factor: 8.168

Review 6. Overcoming resistance to BRAF inhibitors.

Authors: Imanol Arozarena; Claudia Wellbrock
Journal: Ann Transl Med Date: 2017-10

Review 7. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Authors: Sarah J Welsh; Pippa G Corrie
Journal: Ther Adv Med Oncol Date: 2015-03 Impact factor: 8.168

Review 8. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

Authors: Aleksei V Novik; Svetlana A Protsenko; Irina A Baldueva; Aleksander O Ivantsov; Tatyana L Nekhaeva; Zinaida Y Akhaeva; Grigoriy A Yanus; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal: Target Oncol Date: 2016-04 Impact factor: 4.493

9. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Authors: Douglas B Johnson; Keith T Flaherty; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Richard F Kefford; Omid Hamid; Lynn Schuchter; Jonathan Cebon; William H Sharfman; Robert R McWilliams; Mario Sznol; Donald P Lawrence; Geoffrey T Gibney; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Kiran Patel; Nageatte Ibrahim; Peng Sun; Shonda Little; Elizabeth Cunningham; Jeffrey A Sosman; Adil Daud; Rene Gonzalez
Journal: J Clin Oncol Date: 2014-10-06 Impact factor: 44.544

Review 10. Somatic DNA mutation analysis in targeted therapy of solid tumours.

Authors: Bing Yu; Sandra A O'Toole; Ronald J Trent
Journal: Transl Pediatr Date: 2015-04